APOE genotype and cognitive decline in a middle-aged cohort

C. K. Blair, A. R. Folsom, D. S. Knopman, M. S. Bray, T. H. Mosley, E. Boerwinkle

Research output: Contribution to journalArticle

93 Scopus citations

Abstract

Background: Most longitudinal studies of nondemented persons have reported greater cognitive decline among APOE ε4 carriers vs noncarriers. However, most studies involved elderly samples (aged 65+) and were not large enough to examine the three APOE alleles separately. Methods: Change in cognitive function was examined over a 6-year period using three neuropsychological tests among four APOE genotype groups (ε2/2 + ε2/3, ε3/3 (referent), ε4/2 + ε4/3, ε4/4). The population-based sample included 1,693 African Americans and 6,202 Caucasians initially ages 47 to 68. Results: There was increasingly greater cognitive decline from the ε2 group to the ε4/4 group in Caucasians for two of the three tests. The combination of APOE ε4 with hypercholesterolemia or diabetes showed the greatest cognitive decline. Among African Americans, only the test measuring psychomotor speed showed associations with APOE genotype. Conclusions: APOE ε4 is associated with greater cognitive decline in middle-aged Caucasian individuals, with a reduced decline among ε2 carriers. This suggests that the processes by which APOE genotype mediates dementia risk are operative well in advance of overt dementia.

Original languageEnglish (US)
Pages (from-to)268-276
Number of pages9
JournalNeurology
Volume64
Issue number2
DOIs
StatePublished - Jan 25 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'APOE genotype and cognitive decline in a middle-aged cohort'. Together they form a unique fingerprint.

  • Cite this

    Blair, C. K., Folsom, A. R., Knopman, D. S., Bray, M. S., Mosley, T. H., & Boerwinkle, E. (2005). APOE genotype and cognitive decline in a middle-aged cohort. Neurology, 64(2), 268-276. https://doi.org/10.1212/01.WNL.0000149643.91367.8A